Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Alighieri who wrote (523814)	10/27/2009 11:43:49 AM
From: i-node	Read Replies (2) \| Respond to of 1578999

>> Generic drugs...much higher use of generic drugs... The generic substitution rate for Part D has increased a few percentage points since its inception and that is great. That said, competition is the primary driver of success for the Part D program. The strong generic substitution rate is a direct result of the structure of the Part D program which motivates the consumer to use less expensive drugs where available. Part D is a model for a well-run government-based health care system. In multiple respects -- - promotes competition - promotes cost-effective utilization - gives consumers choice - eliminates government bloat in the program - beats budget estimates, consistently (due to above) This is why even though I didn't want the program to begin with, it is tolerable to me and I don't consider it to be a failure like SS or Parts A & B.